Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine
Multiple Myeloma and Plasma Cell Neoplasm
Jan WalewskivaccineN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Multiple Myeloma and Plasma Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Busulphan M.D. Anderson Cancer Center | Phase 4 | BBB |
Inno-206 University of Arkansas | Phase 3 | BBB |
VINCRISTINE SULFATE Roswell Park Cancer Institute | Phase 3 | BBB |
CYCLOSPORIN A Seoul National University Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →